IndustryCompany release

Merit Medical acquires Solo Pace for about $45m, adding TAVR temporary pacing systems

🇺🇸 Merit Medical Systems Inc (MMSI) · Thu 29 Oct 2026

Merit Medical bought the remaining equity in Solo Pace, its exclusive distributor partner, bringing the FDA-cleared SOLO PACE CONTROL and FUSION pacing systems in-house.

Merit Medical Systems announced on 29 October 2026 that it had acquired all remaining equity of Solo Pace, Inc. The deal closed on 13 October 2026 and was valued at roughly $45m.

Merit already held about 18% of Solo Pace and acted as its exclusive distributor, so the transaction converts an existing commercial and financial relationship into full ownership.

Solo Pace makes the SOLO PACE CONTROL and FUSION temporary pacing systems. They are used in transcatheter aortic valve replacement (TAVR) and other transcatheter heart valve procedures for patients with aortic stenosis.

FUSION received FDA 510(k) clearance, which was announced in April 2025, and was commercially released in March 2026. A 510(k) clearance is the US route by which a device is cleared by showing it is substantially equivalent to a legally marketed predicate device.

Merit expects the acquisition to be immaterial to its 2026 results and slightly accretive to non-GAAP earnings in 2027.

What it means for your team

  • Manufacturer ownership of the Solo Pace products has now moved to Merit, so teams tracking the devices should confirm who holds regulatory and quality responsibilities as integration proceeds.
  • Hospital procurement and market-access teams working with TAVR pacing may see changes in contracting and supply, since Merit was previously the exclusive distributor.
  • FUSION has been commercially available only since March 2026, so post-market experience with it is still at an early stage.

Company's press release (SEC filing): Merit Medical Systems Inc ↗

Article written by VigiEye from the official source (Merit Medical Systems Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →